Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments

[ad_1] A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years. The study was published today in the Journal of Cystic Fibrosis. “This is incredibly meaningful…

Read More